RT Journal Article
SR Electronic
T1 DeepDrug: An Expert-led Domain-specific AI-Driven Drug-Repurposing Mechanism for Selecting the Lead Combination of Drugs for Alzheimer’s Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.06.24309990
DO 10.1101/2024.07.06.24309990
A1 Li, Victor OK
A1 Han, Yang
A1 Kaistha, Tushar
A1 Zhang, Qi
A1 Downey, Jocelyn
A1 Gozes, Illana
A1 Lam, Jacqueline CK
YR 2024
UL http://medrxiv.org/content/early/2024/07/07/2024.07.06.24309990.abstract
AB Alzheimer’s Disease (AD) significantly aggravates human dignity and quality of life. While newly approved amyloid immunotherapy has been reported, effective AD drugs remain to be identified. Here, we propose a novel AI-driven drug-repurposing method, DeepDrug, to identify a lead combination of approved drugs to treat AD patients. DeepDrug advances drug-repurposing methodology in four aspects. Firstly, it incorporates expert knowledge to extend candidate targets to include long genes, immunological and aging pathways, and somatic mutation markers that are associated with AD. Secondly, it incorporates a signed directed heterogeneous biomedical graph encompassing a rich set of nodes and edges, and node/edge weighting to capture crucial pathways associated with AD. Thirdly, it encodes the weighted biomedical graph through a Graph Neural Network into a new embedding space to capture the granular relationships across different nodes. Fourthly, it systematically selects the high-order drug combinations via diminishing return-based thresholds. A five-drug lead combination, consisting of Tofacitinib, Niraparib, Baricitinib, Empagliflozin, and Doxercalciferol, has been selected from the top drug candidates based on DeepDrug scores to achieve the maximum synergistic effect. These five drugs target neuroinflammation, mitochondrial dysfunction, and glucose metabolism, which are all related to AD pathology. DeepDrug offers a novel AI-and-big-data, expert-guided mechanism for new drug combination discovery and drug-repurposing across AD and other neuro-degenerative diseases, with immediate clinical applications.Competing Interest StatementThis work including contribution of six of the co-authors is under patent protection (University of Hong Kong and Tel Aviv University).Funding StatementThis research was supported in part by the US National Academy of Medicine (NAM) Healthy Longevity Catalyst Award 2021 and "An Artificial Intelligence (AI)-driven Causal Approach for Early Diagnosis and Treatment of Late Onset Alzheimer's Disease" under Seed Fund for Collaborative Research, The University of Hong Kong, June 2023.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe drug and drug-drug interaction data were obtained from DrugBank (https://go.drugbank.com). The drug target data were obtained from DrugBank (https://go.drugbank.com), DrugCentral (https://drugcentral.org), ChEMBL (https://www.ebi.ac.uk/chembl/), and BindingDB (https://www.bindingdb.org/). The protein-protein interaction and pathway data were obtained from STRING (https://string-db.org).